Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Re-purposing cancer therapeutics for breast cancer immunotherapy.

Emens LA.

Cancer Immunol Immunother. 2012 Aug;61(8):1299-305. doi: 10.1007/s00262-012-1247-z. Epub 2012 Mar 28. Review.

2.

Towards a therapeutic breast cancer vaccine: the next steps.

Emens LA.

Expert Rev Vaccines. 2005 Dec;4(6):831-41. Review.

PMID:
16372879
3.

Immunotherapy for the treatment of breast cancer.

Ernst B, Anderson KS.

Curr Oncol Rep. 2015 Feb;17(2):5. doi: 10.1007/s11912-014-0426-9. Review.

PMID:
25677118
4.

Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.

Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A.

Breast. 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review.

PMID:
24074802
5.

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.

Chen Y, Xie Y, Chan T, Sami A, Ahmed S, Liu Q, Xiang J.

Cancer Gene Ther. 2011 Jul;18(7):489-99. doi: 10.1038/cgt.2011.18. Epub 2011 May 13.

PMID:
21566669
6.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.

Oncogene. 1998 Oct 29;17(17):2235-49.

7.

Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.

Emens LA, Reilly RT, Jaffee EM.

Endocr Relat Cancer. 2005 Mar;12(1):1-17. Review.

8.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
9.

Immunotherapy and cancer vaccines in the management of breast cancer.

Sauer G, Kurzeder C, Heilmann V, Kreienberg R, Deissler H.

Curr Pharm Des. 2005;11(27):3475-83. Review.

PMID:
16248802
10.

Target-based therapies in breast cancer: current status and future perspectives.

Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F.

Endocr Relat Cancer. 2009 Sep;16(3):675-702. doi: 10.1677/ERC-08-0208. Epub 2009 Jun 12. Review.

11.

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

Emens LA, Reilly RT, Jaffee EM.

Breast Dis. 2004;20:13-24. Review.

PMID:
15687703
12.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
13.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
14.

Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.

Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, Von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW 2nd, Urba WJ, Fox BA.

J Immunother. 2003 Mar-Apr;26(2):163-70.

PMID:
12616108
15.

Developing an effective breast cancer vaccine.

Soliman H.

Cancer Control. 2010 Jul;17(3):183-90. Review.

16.

Immunotherapy strategies in the treatment of breast cancer.

Soliman H.

Cancer Control. 2013 Jan;20(1):17-21. Review.

17.
18.

Immunotherapy of colorectal cancer.

Beatty JD.

Cancer. 1992 Sep 1;70(5 Suppl):1425-33. Review.

19.

The immune system and response to HER2-targeted treatment in breast cancer.

Bianchini G, Gianni L.

Lancet Oncol. 2014 Feb;15(2):e58-68. doi: 10.1016/S1470-2045(13)70477-7. Review.

PMID:
24480556
20.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739

Supplemental Content

Support Center